Agents Targeted Against PSMA for Prostate Cancer
Scott T. Tagawa, MD, MS, associate professor, Clinical Medicine and Urology, Weill Cornell Medical College, discusses PSMA-targeting agents for the treatment of prostate cancer.
Clinical Pearls
Scott T. Tagawa, MD, MS, associate professor, Clinical Medicine and Urology, Weill Cornell Medical College, discusses PSMA-targeting agents for the treatment of prostate cancer.
- As resistance to AR-targeted therapy develops, PSMA expression will increase in many patients. An agent targeted against PSMA could be added in at this time.
- PSMA-targeted therapy could also potentially be used in combination with AR-targeted therapy.
- Both AR- and PSMA-targeted therapies are being investigated in clinical trials and are already making an impact.
Recent Videos
Related Content
Novel Frontline Treatments Add Layer of Complexity in Urothelial Carcinoma
January 2nd 2025Article
The past 12 months have seen the FDA approvals of enfortumab vedotin plus pembrolizumab for patients with locally advanced or metastatic urothelial cancer and nivolumab plus cisplatin and gemcitabine for patients with unresectable or metastatic urothelial carcinoma.
Read More
